Transformation of FL into DLBCL with a PMBL gene expression signature.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
28 03 2023
Historique:
accepted: 06 09 2022
received: 17 02 2022
pubmed: 15 10 2022
medline: 21 3 2023
entrez: 14 10 2022
Statut: ppublish

Résumé

We investigated the clinicopathologic features of 5 follicular lymphomas (FLs) that transformed (tFL) morphologically to diffuse large B-cell lymphomas (DLBCLs) and had a primary mediastinal large B-cell lymphoma (PMBL)-like gene expression profile (tFL-PMBLsig-pos). None of the tFL-PMBLsig-pos cases arose in the mediastinum, all cases tested had a germinal center B-cell phenotype, 20% were CD30+, 60% CD23+, 80% MAL+, 20% CD200+, and 0% CD273/PDL2+. Whole-exome sequencing detected alterations in genes associated with both FL/DLBCL (CREBBP, KMT2C, KMT2D, ARID1A, HIST1 members, and TNFRSF14) and PMBL (JAK-STAT pathway genes, B2M, and CD58). Copy number (CN) analysis detected gains/amplification of REL and STAT6 in 60%, gains of SOCS1 in 40%, and gains of chromosome 16, including IL4R, in 40% of the cases. CN gains/amplification of BCL6 and MYC and loss of TNFRSF14 and TNFAIP3 were identified in 20% of the cases. Three of 5 cases lacked a BCL2 rearrangement. Despite having some features that are less common in DLBCL (MAL and CD23 expression and JAK-STAT activation), these tFL-PMBLsig-pos cases lack the most characteristic CN alteration seen in PMBL (9p24.1 gain/amplification). This cohort expands the biologic heterogeneity of tFL, illustrating a subset with gene expression and some genetic features reminiscent of PMBL, with potential treatment implications that include the use of novel targeted therapies.

Identifiants

pubmed: 36240289
pii: 486786
doi: 10.1182/bloodadvances.2022007360
pmc: PMC10025110
doi:

Substances chimiques

Janus Kinases EC 2.7.10.2
STAT Transcription Factors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

893-899

Informations de copyright

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

J Hematop. 2019 Mar;12(1):3-10
pubmed: 34447482
Blood. 2014 Mar 13;123(11):1681-90
pubmed: 24037725
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13015-13020
pubmed: 27803324
Blood. 2008 Jun 15;111(12):5433-9
pubmed: 18272816
Blood. 2020 Jan 23;135(4):274-286
pubmed: 31738823
Cell Rep. 2014 Jan 16;6(1):130-40
pubmed: 24388756
Blood. 2015 Oct 29;126(18):2118-27
pubmed: 26307535
Blood. 2021 Jul 15;138(2):136-148
pubmed: 33684939
Blood. 2018 Nov 29;132(22):2401-2405
pubmed: 30257882
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
Ann Oncol. 1998 Jul;9(7):717-20
pubmed: 9739436
Hum Pathol. 2018 Jan;71:91-99
pubmed: 29122656
Blood. 2019 Sep 5;134(10):802-813
pubmed: 31292115
Haematologica. 2019 Sep;104(9):1822-1829
pubmed: 30733272
Hum Pathol. 2020 Aug;102:33-43
pubmed: 32540222
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
J Clin Oncol. 2007 Jun 10;25(17):2426-33
pubmed: 17485708
Oncogene. 2002 Jun 27;21(28):4351-62
pubmed: 12080466
Blood. 1997 Jun 1;89(11):3909-18
pubmed: 9166827
Blood Cancer J. 2019 Aug 30;9(9):73
pubmed: 31471540
J Clin Oncol. 2008 Nov 10;26(32):5165-9
pubmed: 18838711
Am J Surg Pathol. 2017 Feb;41(2):189-194
pubmed: 27879516
Blood. 2018 May 24;131(21):2297-2306
pubmed: 29666116

Auteurs

Tristan Loveday (T)

Alix School of Medicine, Mayo Clinic, Scottsdale, AZ.

Gerben Duns (G)

Centre for Lymphoid Cancer, British Columbia (BC) Cancer, Vancouver, BC.

Lisa M Rimsza (LM)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ.

Karen L Rech (KL)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

James R Cook (JR)

Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.

Ryan S Robetorye (RS)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ.

Allison C Rosenthal (AC)

Division of Hematology/Medical Oncology, Mayo Clinic, Phoenix, AZ.

Colleen A Ramsower (CA)

Department of Research, Mayo Clinic, Scottsdale, AZ.

Tameson K Yip (TK)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ.

Catherine L McKinney (CL)

Department of Research, Mayo Clinic, Scottsdale, AZ.

Steven H Swerdlow (SH)

Division of Hematopathology, University of Pittsburgh School of Medicine/UPMC, Pittsburgh, PA.

Shweta Bhavsar (S)

Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH.
Division of Hematopathology, University of Pittsburgh School of Medicine/UPMC, Pittsburgh, PA.

Christian Steidl (C)

Centre for Lymphoid Cancer, British Columbia (BC) Cancer, Vancouver, BC.

Sarah E Gibson (SE)

Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH